LIDDS presents at Redeye Growth Day

Non Regulatory

UPPSALA, SWEDEN – LIDDS AB (publ) announce today that Nina Herne will participate at Redeye Growth Day on June 2, 2022.

Nina Herne, CEO of LIDDS, will present the company at Redeye Growth Day at Haymarket by Scandic, Hötorget 13-15 in Stockholm at 09.50 CET on June 2, 2022. The presentation is live broadcasted and can be followed at Redeye Growth Day 2022.

For additional information, please contact

Nina Herne, CEO
Phone: +46 (0)70 714 74 57
E-mail: nina.herne@liddspharma.com
 
Jenni Björnulfson, CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS’ Certified Adviser is Redeye AB
Tel: +46 (0)8 121 576 90
E-mail: certifiedadviser@redeye.se

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and solve problems within many indication areas. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage development, and projects about to enter clinical phase. The company is listed on Nasdaq First North Growth market.

Attachments

LIDDS presents at Redeye Growth Day